Perspectives on Comparative Data for Software- and Cognitive-Based Fusion Biopsies

Dr. Amir H. Lebastchi reviews retrospective data comparing software-based and cognitive-based fusion biopsy approaches, providing valuable insights into the findings.

EP: 1.Landscape Surrounding Prostate Cancer Screening

EP: 2.Updates in Approaches for Prostate Cancer Biopsy and Diagnosis

EP: 3.The Evolving Landscape Surrounding Fusion-Guided Prostate Biopsy

Now Viewing

EP: 4.Perspectives on Comparative Data for Software- and Cognitive-Based Fusion Biopsies

EP: 5.Leveraging MRI and Fusion-Guided Biopsy for Active Surveillance in Prostate Cancer

EP: 6.Integrating MRI and Ultrasound Fusion-Based Technology for Personalized Focal Therapy in Prostate Cancer

EP: 7.Expert Perspectives on the VIOLETTE Study and Future Directions in Prostate Cancer Research

Related Videos

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.

Related Content

Advertisement

February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke

The primary end point is 12-month radiographic progression-free survival.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke

The data also showed that mortality plateaued in recent years despite declining in years prior.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke

“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.

January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke

Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.